Daniel S. Lorrain, Chief Scientific Officer at Contineum Therapeutics, Inc. (CTNM), sold 1,040 shares at $16.00 ($17K) on 2026-07-08, disclosed to the SEC on 2026-07-10.
Scheduled sale ($17k) by Chief Scientific Officer under a pre-arranged 10b5-1 plan. Pre-set trade — not a discretionary signal on the stock.
Negative factors outweigh the positive ones.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $16.00 | 1,015 | $16K | 97.6% |
| 2 | $16.00 | 25 | $400 | 2.4% |
| Total | $16.00 avg | 1,040 | $17K | 100% |
| Filing → |
| CTNM | SELL | 2026-05-01 | $55K | — | Filing → |
| CTNM | SELL | 2026-04-06 | $56K | — | Filing → |
| CTNM | SELL | 2026-03-02 | $63K | — | Filing → |